Skip to main content
FDA Updates, Neuroblastoma
Danyelza First Drug FDA Approved for High-Risk Neuroblastoma in the Bone and Bone Marrow
Read More
FDA Updates, Lung Cancer
Gavreto, a New RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions
Read More
FDA Updates, Leukemia
Onureg FDA Approved for Adults with AML in Remission
Read More
FDA Updates, Thyroid Cancer
Gavreto Now Approved for Thyroid Cancer with RET Fusions
Read More
FDA Updates, Breast Cancer
Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer
Read More
FDA Updates, Lymphoma
Keytruda Approved for Relapsed or Refractory Classical Hodgkin Lymphoma
Read More
FDA Updates, Mesothelioma
Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma
Read More
Cholangiocarcinoma
A Comprehensive Genomic Profiling Study Comparing Primary Tumor, Metastatic Tumor Tissue, and Liquid Biopsy in Patients with Intrahepatic CCA
Read More
Cholangiocarcinoma
PROOF Trial: A Multicenter, Open-Label Randomized, Phase 3 Trial of Infigratinib versus Gemcitabine plus Cisplatin in Patients with Advanced CCA with FGFR2 Gene Rearrangements
Read More
Cholangiocarcinoma
The Worldwide Incidence of Biliary Tract Cancer
Read More
Page 118 of 199
Results 1171 - 1180 of 1986